Observational Study on Patients With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma Clinical Trial

Official title:

Observational Study on Patients With Hepatocellular Carcinoma (HCC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04021056
• Other study ID #: NFHCC-01
• Status: Recruiting
• Start date: January 1, 2011
• Est. completion date: December 31, 2022

Study information

• Verified date: July 2019
• Source: Nanfang Hospital of Southern Medical University
• Contact: Jinlin Hou
• Email: jlhousmu[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 31, 2022
• Est. primary completion date: August 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of HCC;

• Age = 16 years;

• Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;

• Good compliance with clinical treatment.

Exclusion Criteria:

• Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;

• Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time = 7 days;

• HCC diagnosed after liver transplantation;

• Poor compliance or important data deficient.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Other:
• No intervention

Locations

Country	Name	City	State
China	Nanfang Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Nanfang Hospital of Southern Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the overall survival rate of all HCC patients	In order to identify the potential influence factors of HCC patients survival	10 years
Primary	Evaluate the recurrence free survival rate of HCC patients after curative treatments	In order to identify the potential influence factors of tumor recurrence	10 years